Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nvct · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$10.00
+6.2% upside
Low
$10.00
Median: $10 · Last Close: $9.42
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $8.95 | ↓ 5.00% |
1-day model range: $8.87–$9.03. Peak: $9.03 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $10 | +2.0% |
| 2028 | $10 | +3.0% |
| 2029 | $10 | +3.6% |
| 2030 | $10 | +3.8% |
| 2031 | — | +4.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NVCT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-03-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-07-13 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2022-05-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Nuvectis Pharma, Inc. (NVCT) stock. Of the recent 11 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover NVCT.
Analyst Recommendation Trends
NVCT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↓ 74.2% YoY
Revenue Next Year
$26M
↑ 779.6% YoY
EPS This Year
$-1.05
EPS Next Year
$-1.07
↑ 2.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast NVCT EPS of $-1.05 for the current fiscal year, based on estimates from 4 analysts. The NVCT revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NVCT stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NVCT price target is $10.00 (+6.2% upside), with an analyst consensus of Buy.
The NVCT short-term stock prediction for tomorrow is $8.95 (-5.00%). The NVCT stock price prediction for 2027 estimates an average of $10. The NVCT stock prediction for 2030 projects a range of $9–$11.
Nuvectis Pharma, Inc. trades on NASDAQ under the ticker NVCT. The NVCT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
NVCT forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month NVCT price target is $10.00, with a high forecast of $10.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +6.2% potential upside from the current price of $9.42.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.